Annex 1: Report on WHO Questionnaire for Review of Psychoactive Substances for the 39th ECDD: Evaluation of 5F-PB-22

Data was obtained from 57 Member States (7 AFR, 4 EMR, 25 EUR, 7 PAH, 2 SEAR and 12 WPR) for the WHO Questionnaires for the Review of Psychoactive Substances.

A total of 46 Member States answered the questionnaire regarding 5F-PB-22. Of these, 16 respondents had information on the substance.

Region	Number of countries responded	Number of countries with information on substance
AFR	6	0
EMR	3	0
EUR	21	13
PAH	5	1
SEAR	2	0
WPR	9	2
TOTAL	46	16

LEGITIMATE USE

No countries reported any approved human medical products or veterinary products containing 5F-PB-22.

5F-PB-22 is not currently being used in any medical or scientific research (excluding use as an analytical reference standard) or for any industrial purposes.

No countries reported the use of 5F-PB-22 for any cultural, religious or ceremonial purposes.

EPIDEMIOLOGY OF NON-MEDICAL/NON-SCIENTIFIC USE – USE FOR PSYCHOACTIVE PURPOSES OR RECREATIONAL DRUG USE

There were 12 countries that reported 5F-PB-22 as being misused for its psychoactive properties (as a recreational drug).

Smoking was reported to be the main route of administration for 5F-PB-22 (refer to Table 1). One country reported that 5F-PB-22 is dissolved into a solution and then smoked either through an e-cigarette or by being applied to plant materials.

Route of administration	Number of countries
Smoking	6
Inhalation	1
Sniffing	0
Oral	0
Injection	0
Don't know	7
Other	1

Table 1: Common routes of administration

The common formulation of 5F-PB-22 reported was powder (refer to Table 2). Seven countries also reported that 5F-PB-22 is generally dissolved in solvents and administered to leaf or plant material before being smoked. Also, one country stated that powder may be dissolved into liquid for e-cigarette use.

Formulations	Number of countries
Powder	12
Liquid for oral use	1
Tablets	0
Solution for injection	0
Other	7

Table 2: Common formulations reported by countries

Smuggling was the source of 5F-PB-22 for non-medical/non-scientific in eight countries (refer to Table 3).

Sources	Number of countries
Smuggling	8
Illegal manufacturing	1
Legal manufacturing	0
Legal trade	0
Diversion	0
Don't know	4

Table 3: Sources of substance for non-medical or non-scientific use

The level of negative health-impact originating from this substance's non-medical consumption was reported as:

Serious	Substantial	Negligible	Don't Know
4	0	3	5

Annex 1: WHO Questionnaire

Those countries which reported a serious or substantial level of negative health-impact indicated that this level was chosen due to the association of 5F-PB-22 with serious adverse effects including fatalities.

Two countries reported emergency room admissions related to the non-medical use of 5F-PB-22. Reported serious adverse effects included dizziness, mydriasis, tachycardia, discomfort, diaphoresis, multi-organ failure (liver, kidney, circulatory, CNS), cardiac arrest, pulmonary oedema and death.

In regards to the mortality rate, data was provided by two countries. The rate where <u>only</u> 5F-PB-22 was involved included two cases in 2013. The rate <u>which included involvement of other substances</u> was reported to be three cases in 2013. Finally the rate, where it was <u>unknown if</u> other substances were involved was one case in 2014.

STATUS OF NATIONAL CONTROL AND POTENTIAL IMPACT OF INTERNATIONAL CONTROL

There were 12 countries which reported that 5F-PB-22 was under national control. The legislation that the control is based upon included the Controlled Substances Act (7 countries), Medicines Act (2 countries), and other specific legislation (3 countries). One country reported challenges to implementing controls including forensic laboratory capacity, resources to implement and/or enforce and expertise to detect or enforce.

The scope of the controls includes production (12 countries), manufacturing (12 countries), exporting (11 countries), importing (12 countries), distribution (12 countries), use (7 countries) and possession (11 countries).

Reported illicit activities involving 5F-PB-22 (Table 4) include:

Illicit Activities	Number of countries
Internet sales from unknown locations	5
Trafficking	3
Internet sales from abroad	3
Sales to people who use the substance	2
Internet sales within your country	1
Manufacture of substance by chemical	0
synthesis	
Manufacture of substance by extraction	0
from other products	
Production of consumer products	0
Don't know	5

Table 4: Reported illicit activities involving 5F-PB-22

Annex 1: WHO Questionnaire

There were nine countries which completed the section on the number of seizures. The combined number of seizures was 1501 (2014), 499 (2015) and 101 (2016).

If 5F-PB-22 was placed under international control, sixteen countries responded that they would have the capacity to enforce the control at the national level. There were fifteen countries which responded that they would have the forensic laboratory capacity to analyse the substance.